Abstract
The proglucagon-derived peptide hormone, glucagon, comprises 29 amino acids. Its secretion from the pancreatic α cells is regulated by several factors. Glucagon increases blood glucose levels through gluconeogenesis and glycogenolysis. Elevated plasma concentrations of glucagon, hyperglucagonemia, may contribute to diabetes. However, hyperglucagonemia is also observed in other clinical conditions than diabetes, including nonalcoholic fatty liver disease, glucagon-producing tumors and after gastric bypass surgery. Here, we review the current literature on hyperglucagonemia in disease with a particular focus on diabetes, and finally speculate that the primary physiological importance of glucagon may not reside in glucose homeostasis but in regulation of amino acid metabolism exerted via a hitherto unrecognized hepato-pancreatic feedback loop.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes. Metabol. 13, 118–125 (2011).
- 2 . Hyperglucagonemia and its suppression. N. Engl. J. Med. 299(9), 433–436 (1978).
- 3 . Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 46(12), 1954–1962 (1967).
- 4 . Aqueous extracts of pancreas: III. Some precipitation reactions of insulin. J. Biol. Chem. 58(1), 337–346 (1923).
- 5 . Role of glucagon and insulin in control of glucose turnover. Metabolism 20(6), 625–628 (1971).
- 6 . Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 35(2), 170–190 (1956).
- 7 . Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122(1), 4–12 (2012). • An essential review on the glucagonocentric hypothesis by Professor Unger.
- 8 . Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am. J. Physiol. 236(3), E263–E271 (1979).
- 9 . The effect of intraportal and peripheral infusions of glucagon on insulin and glucose concentrations and glucose tolerance in normal man. Diabetologia 13(5), 487–490 (1977).
- 10 . Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45(8), 1076–1083 (1996).
- 11 . Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12(3), 141–146 (1922).
- 12 A randomized, double-blind, placebo-controlled Phase 2 study of the glucagon receptor antagonist LY2409021 in patients with Type 2 diabetes. Diabetes Care
doi:10.2337/dc15-1643 (2015) (Epub ahead of print). - 13 . Glucagon antagonism as a potential therapeutic target in Type 2 diabetes. Diabetes Obes. Metab. 13(11), 965–971 (2011).
- 14 Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of α-cell mass. Cell Rep. 12(3), 495–510 (2015). •• The first paper that identified amino acids as potential regulators of α-cell survival and function.
- 15 . Palmitate stimulation of glucagon secretion in mouse pancreatic alpha-cells results from activation of L-type calcium channels and elevation of cytoplasmic calcium. Diabetes 53(11), 2836–2843 (2004).
- 16 . Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38(4), 665–673 (1993).
- 17 . Oxyntomodulin (glicentin-[33–69]): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul. Pept. 21(1–2), 151–166 (1988).
- 18 Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycemia. Diabetologia 46(6), 798–801 (2003).
- 19 . Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60(12), 3103–3109 (2011).
- 20 . Autonomic nervous control of the endocrine secretion from the isolated, perfused pig pancreas. J. Auton. Nerv. Syst. 17(1), 71–84 (1986).
- 21 Regulation of glucagon secretion by incretins. Diabetes Obes. Metab. 13(Suppl. 1), 89–94 (2011).
- 22 . The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59(7), 1765–1770 (2010).
- 23 . Intra-islet glucagon secretion and action in the regulation of glucose homeostasis. Front. Physiol. 3, 485 (2012).
- 24 . α-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28(1), 84–116 (2007).
- 25 . Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137(11), 5119–5125 (1996).
- 26 . Insulin reciprocally regulates glucagon secretion in humans. Diabetes 59(11), 2936–2940 (2010).
- 27 Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 9(4), 350–361 (2009).
- 28 Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45(2), 257–261 (1996).
- 29 . Dual glucagon recognition by pancreatic β-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 47(1), 66–72 (1998).
- 30 Oxyntomodulin identified as a marker of Type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma. EBioMedicine
doi:10.1016/j.ebiom.2016.03.034 (2016) (Epub ahead of print). - 31 . Islet α cells and glucagon – critical regulators of energy homeostasis. Nat. Rev. Endocrinol. 11(6), 329–338 (2015).
- 32 Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62(5), 1453–1463 (2013).
- 33 FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab. 23(2), 335–343 (2016).
- 34 . Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60(11), 2758–2762 (2011).
- 35 . Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 345(6271), 158–161 (1990).
- 36 Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J. Gastroenterol. 33(6), 835–841 (1998).
- 37 . Alpha-, delta- and PP-cells: are they the architectural cornerstones of islet structure and co-ordination? J. Histochem. Cytochem. 63(8), 575–591 (2015).
- 38 . Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95(2), 513–548 (2015).
- 39 Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur. J. Endocrinol. 170(4), 529–538 (2014).
- 40 . Evaluating assay precision. Clin. Biochem. Rev. 29(Suppl. 1), S23–S26 (2008).
- 41 . Circulating glucagon after total pancreatectomy in man. Diabetologia 25(5), 396–399 (1983).
- 42 . Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs: a quantitative assessment of secretion rates and anatomical delineation of sources. J. Clin. Invest. 62(1), 124–132 (1978).
- 43 Evidence of extrapancreatic glucagon secretion in man. Diabetes 65(3), 585–597 (2015).
- 44 . Extrapancreatic glucagons. Digestion 17(2), 168–190 (1978).
- 45 Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57(9), 1919–1926 (2014).
- 46 Effect of aprotinin (Trasylol™) on degradation of exogenous and endogenous glucagon in human, mouse and rat plasma. J. Endocrinol. Diabetes 1(1), 5 (2014).
- 47 Inability of some commercial assays to measure suppression of glucagon secretion. J. Diabetes Res. 2016, 5 (2016).
- 48 Stability of glucagon-like peptide-1 and glucagon in human plasma. Endocr. Connect. 4(1), 50–57 (2015).
- 49 . Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metabol. 64(1), 106–110 (1987).
- 50 . Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest. 49(4), 837–848 (1970).
- 51 Impaired incretin effect and fasting hyperglucagonaemia characterizing Type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes. Metab. 14(6), 500–510 (2012).
- 52 Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326(1), 22–29 (1992).
- 53 . Pancreatic α-cell dysfunction in Type 2 diabetes: old kids on the block. Diabetes Metab. J. 39(1), 1–9 (2015).
- 54 . Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in Type 2 diabetes mellitus. Diabetologia 50(4), 797–805 (2007).
- 55 . Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with Type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 298(4), E832–E837 (2010).
- 56 Glucagon receptor antibody completely suppresses Type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc. Natl Acad. Sci. USA 112(8), 2503–2508 (2015).
- 57 . Glucagon receptor knockout prevents insulin-deficient Type 1 diabetes in mice. Diabetes 60(2), 391–397 (2011).
- 58 . Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37(10), 985–993 (1994).
- 59 Glucagon receptor blockade with a human antibody normalizes blood glucose in diabetic mice and monkeys. Endocrinology 156(8), 2781–2794 (2015).
- 60 Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia 59(2), 363–370 (2015).
- 61 Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl Acad. Sci. USA 100(3), 1438–1443 (2003).
- 62 Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes 62(4), 1196–1205 (2012).
- 63 Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes 64(3), 819–827 (2015).
- 64 Metabolic response to sodium-glucose cotransporter 2 inhibition in Type 2 diabetic patients. J. Clin. Invest. 124(2), 499–508.
- 65 . Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44(11), 1998–2003.
- 66 . Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 32(3), 439–444 (2009).
- 67 Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. Am. J. Physiol. 301(6), E1174–E1183 (2011).
- 68 Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab. 19(4), 667–681 (2014).
- 69 . Do glucagonomas always produce glucagon? Bosn. J. Basic Med. Sci. 16(1), 1–7 (2016).
- 70 . Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 24(5), 359–365 (1983).
- 71 Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinol. Diabetes Metabol. Case Rep. 2015, 150105 (2015).
- 72 . Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin. Endocrinol. (Oxf.) 57(6), 827–831 (2002).
- 73 GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinol. Diabetes Metabol. Case Rep. 2015, 150049 (2015).
- 74 . Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41(10), 1180–1186 (1998).
- 75 . The physiology of glucagon. J. Diabetes Sci. Technol. 4(6), 1338–1344 (2010).
- 76 . Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels. Diabetes Obes. Metab. 18(1), 34–39 (2016).
- 77 Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals. J. Clin. Endocrinol. Metabol. 97(5), E791–E795 (2012).
- 78 . Pulsatility does not alter the response to a physiological increment in glucagon in the conscious dog. Am. J. Physiol. 266(3 Pt 1), E467–E478 (1994).
- 79 Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. J. Clin. Invest. 120(12), 4425–44352010.
- 80 . Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects. J. Clin. Invest. 75(2), 397–403 (1985).
- 81 . Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS). Exp. Clin. Endocrinol. Diabetes 113(05), 268–274 (2005).
- 82 . Hyperglucagonemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels. Metabolism 28(4), 300–307 (1979).
- 83 Expression cloning and signaling properties of the rat glucagon receptor. Science 259(5101), 1614–1616 (1993).
- 84 . Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell. Endocrinol. 141(1–2), 179–186 (1998).
- 85 . Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290(2), 839–843 (2002).
- 86 Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations. J. Clin. Endocrinol. Metabol. 100(5), E783–E788 (2015).
- 87 Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells. Mol. Endocrinol. 23(12), 1990–1999 (2009).
- 88 . Glucagon replacement via micro-osmotic pump corrects hypoglycemia and α-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 51(2), 398–405 (2002).
- 89 . Glucagon immunoneutralization in diabetic rats normalizes urea synthesis and decreases nitrogen wasting. Diabetes 41(1), 12–16 (1992).
- 90 Transcriptional regulation of N-acetylglutamate synthase. PLoS ONE 7(2), e29527 (2012).
- 91 . Transcriptional regulation of genes for ornithine cycle enzymes. Biochem. J. 312(Pt 3), 649–659 (1995).
- 92 Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes 61(1), 74–84 (2012).
- 93 . Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J. Intern. Med. 279(5), 485–493 (2016). • Hyperglucagonemia identified in subjects with fatty liver disease independent of glycemic index supporting the concept of a glucagon feedback loop between the liver and pancreas.